Here are a few stock ideas from leading brokerage houses in the country
Sudarshan Sukhani of s2analytics.com advises traders to buy Zee Entertainment on dip.
Sukhani told CNBC-TV18, "I would avoid media stocks except Zee Entertainment Enterprises. In media stocks these rallies come on and off and they have not given any sustained up moves. So I would expect that this is more of a managed rally unless proved otherwise. Let the rally be sustained and it will become a focus of interest. Zee Entertain is subdued because of news, it is a buy on dips opportunity. Whenever that impact of news is over I think we should go and buy it. For the rest of the media stocks it is best to avoid them."
Sudarshan Sukhani, s2analytics.com is of the view that one can buy Bajaj Auto , Tata Motors .
Sukhani told CNBC-TV18, "Bajaj Auto was a buy in the morning at Rs 815 and it is gratifying to see it do very well. Bajaj Auto has much more upside but this is no longer a day trade because for the day it has done its bit but for a positional trader, even at current levels there is a buying opportunity. Tata Motors is not in the same class as of now in Bajaj Auto but here also if you skip today and you want to say okay, I want to buy on a dip, I think that is justified."
RK Global has recommended hold rating on Colgate Palmolive(India) with a target of Rs 1563, in its November 29, 2012 research report.
"Colgate Palmolive reported "below expectations" in net sales growth of ~17% YoY to Rs7,924 mn (~6% lower to our estimates) for Q2FY'13. During the quarter the company achieved a volume growth of ~10%. Colgate Palmolive India's market share in the toothpaste markets stood at 54.5%, its highest since 1998, a rare instance of a market leader gaining new ground. Aggressive marketing and a huge 32 jump in advertising spend in the first quarter of FY'13 over a year ago coupled with a launch of new variants across consumer segments has helped the largely single product company drive growth."
Motilal Oswal is bullish on GlaxoSmithKline Pharmaceuticals and has recommended buy rating on the stock with a target of Rs 2277 in its November 27, 2012 research report.
"GlaxoSmithKline Pharmaceuticals (GSK Pharma) GLXO management has guided for topline growth of 12-13% for the next few years, and EBITDA margins sustaining at the current 31-32%. It will be undertaking long-term capex of ~INR5b over next 4-5 years to meet the future volume growth; a strong positive given that GLXO has not incurred any significant capex for quite some time. With cash of over INR20b and no debt, the management is also open to inorganic initiatives to drive growth and fill up portfolio gaps."
DISCLAIMER: GoodReturns provides you with information covering shares, futures and options based on broker's reports as stated on various media. Investors are, however, warned that they should NOT take any buy or sell decision based on these views expressed in the article. Investors should consult their own financial and share advisors before taking purchase or sale decisions. GoodReturns does not take any responsibility for any losses incurred by investors who take their cues from the above article.